# Watch routine care for drug combinations that quietly make cancer treatment worse

Source: https://onco.cc/ideas/idea-tr2-antagonism-surveillance/  
OnCo record `idea-tr2-antagonism-surveillance` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some everyday medicines, such as antibiotics or steroids, seem to blunt immunotherapy. Automatically scanning health records for such harmful pairs would catch them years earlier.

## Summary

Antibiotics, proton-pump inhibitors and corticosteroids are associated with worse outcomes on checkpoint inhibitors in retrospective series, yet these signals took years to surface. A pharmacovigilance-style system that continuously screens clinico-genomic databases for concomitant medications associated with reduced efficacy (not just toxicity) would generate hypotheses for confirmation and, where confirmed, guideline warnings.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Systematic surveillance will identify at least three previously unrecognised efficacy-reducing co-medications for immunotherapy or targeted therapy within two years, at least one of which is confirmed in a randomised or well-controlled study.
- Rationale: Adverse-event pharmacovigilance is mature; efficacy pharmacovigilance is not, even though negative interactions on survival matter more than most side-effects.
- Proposed test: Run signal detection across a large clinico-genomic database for patients on PD-1 inhibitors; validate top signals in an independent registry; publish a ranked list.
- Maturity: early-clinical
- Actor: data

## Sources

- Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017): https://doi.org/10.1016/j.cell.2017.11.009

## Connected records

- companies: [Tempus AI](https://onco.cc/companies/tempus/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy](https://onco.cc/key-papers/paper-palmer-cell/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr2-antagonism-surveillance.json